Literature DB >> 23055883

Combination thrombolytic and anti-platelet therapies in an infant with incomplete kawasaki disease and coronary aneurysms.

Peter N Johnson1, Robert J Kuhn.   

Abstract

A 3-month-old infant was transferred to our facility with persistent fever and concerns for septic shock. A 2-D echocardiogram revealed multiple coronary aneurysms and axillary and coronary artery thrombi, and a diagnosis of incomplete Kawasaki disease (KD) was established. Aggressive therapies including intravenous immunoglobulins, enoxaparin, abciximab, aspirin, and alteplase were used to decrease the size of the coronary aneurysms and inhibit further thrombus formation. After minimal change in the size of coronary aneurysms and in thrombus formation, clopidogrel was added. Approximately 2 weeks after initiation of these therapies, a decrease in the coronary aneurysm size was noted with no signs of thrombus. This case documents successful use of thrombolytic and combination anti-platelet agents (i.e., clopidogrel, abciximab, and aspirin) in an infant with KD and cardiovascular sequelae.

Entities:  

Keywords:  abciximab; alteplase; clopidogrel; incomplete Kawasaki disease; thrombosis

Year:  2008        PMID: 23055883      PMCID: PMC3461989          DOI: 10.5863/1551-6776-13.4.242

Source DB:  PubMed          Journal:  J Pediatr Pharmacol Ther        ISSN: 1551-6776


  28 in total

1.  Time lag in platelet function inhibition by clopidogrel in stroke patients as measured by PFA-100.

Authors:  S Raman; B Jilma
Journal:  J Thromb Haemost       Date:  2004-12       Impact factor: 5.824

2.  ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention-Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention).

Authors:  Sidney C Smith; Ted E Feldman; John W Hirshfeld; Alice K Jacobs; Morton J Kern; Spencer B King; Douglass A Morrison; William W O'neill; Hartzell V Schaff; Patrick L Whitlow; David O Williams; Elliott M Antman; Sidney C Smith; Cynthia D Adams; Jeffrey L Anderson; David P Faxon; Valentin Fuster; Jonathan L Halperin; Loren F Hiratzka; Sharon Ann Hunt; Alice K Jacobs; Rick Nishimura; Joseph P Ornato; Richard L Page; Barbara Riegel
Journal:  J Am Coll Cardiol       Date:  2006-01-03       Impact factor: 24.094

3.  Clopidogrel use in children.

Authors:  Yaron Finkelstein; Laila Nurmohamed; Marina Avner; Lee N Benson; Gideon Koren
Journal:  J Pediatr       Date:  2005-11       Impact factor: 4.406

4.  Intracoronary streptokinase in Kawasaki disease: acute and late thrombolysis.

Authors:  J P Cheatham; J D Kugler; C H Gumbiner; L A Latson; P J Hofschire
Journal:  Prog Clin Biol Res       Date:  1987

Review 5.  Diagnosis and therapy of Kawasaki disease in children.

Authors:  A S Dajani; K A Taubert; M A Gerber; S T Shulman; P Ferrieri; M Freed; M Takahashi; F Z Bierman; A W Karchmer; W Wilson
Journal:  Circulation       Date:  1993-05       Impact factor: 29.690

6.  Thrombolytic action of ticlopidine: possible mechanisms.

Authors:  R J Gryglewski; R Korbut; J Swies; E Kostka Trabka; K Bieroń; J Robak
Journal:  Eur J Pharmacol       Date:  1996-07-11       Impact factor: 4.432

7.  Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.

Authors:  Shlomi Matetzky; Boris Shenkman; Victor Guetta; Michael Shechter; Roy Beinart; Roy Bienart; Ilan Goldenberg; Ilya Novikov; Hanna Pres; Naphtali Savion; David Varon; Hanoch Hod
Journal:  Circulation       Date:  2004-06-07       Impact factor: 29.690

8.  The risks and safety of clopidogrel in pediatric arterial ischemic stroke.

Authors:  Teesta Soman; Mubeen F Rafay; Selina Hune; Anita Allen; Daune MacGregor; Gabrielle deVeber
Journal:  Stroke       Date:  2006-03-09       Impact factor: 7.914

9.  Myocardial infarction and atypical Kawasaki disease in a 3-month-old infant.

Authors:  Trina L Peduzzi; Raymond D Pitetti
Journal:  Pediatr Emerg Care       Date:  2002-10       Impact factor: 1.454

10.  Successful thrombolytic therapy using tissue-type plasminogen activator in Kawasaki disease.

Authors:  S Tsubata; F Ichida; Y Hamamichi; A Miyazaki; I Hashimoto; T Okada
Journal:  Pediatr Cardiol       Date:  1995 Jul-Aug       Impact factor: 1.655

View more
  1 in total

1.  Low-dose antithrombotic treatment in coronary thrombosis of Kawasaki disease.

Authors:  Hua Peng; Zubo Wu; Yalan Liu; Ling Li; Shuangshuang Kong; Jing Wu; Yali Liu
Journal:  Pediatr Cardiol       Date:  2014-10-09       Impact factor: 1.655

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.